# KALA BIO, Inc. (KALA) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_13ba44bcb84b19701b2a · retrieved 2026-08-11T15:52:10.896Z

## Overview
Kala Bio, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.

On July 22, 2026, Kala Bio, Inc. filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933 relating to an offering of up to $250,000,000 of shares of common stock under an At The Market Offering Agreement executed with H.C. Wainwright & Co., LLC on January 8, 2026. The prospectus supplement forms part of the company's effective Form S-3 registration statement (File No. 333-295667), initially filed on May 7, 2026 and declared effective on June 25, 2026.

## Terms
- Counterparty: H.C. Wainwright & Co., LLC · Deal value: $250.0M · Consideration: stock

## Key dates
- Announced 2026-07-23

## Timeline
- 2026-07-23 · 8-K (0001829126-26-007760): 8-K - KALA BIO, Inc. — *Kala Bio, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.* On July 22, 2026, Kala Bio, Inc. filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933 relating to an offering of up to $250,000,000 of shares of common stock under an At The Market Offering Agreement executed with H.C. Wainwright & Co., LLC on January 8, 2026. The prospectus supplement forms part of the company's effective Form S-3 registration statement (File No. 333-295667), initially filed on May 7, 2026 and declared effective on June 25, 2026.
  https://www.sec.gov/Archives/edgar/data/1479419/0001829126-26-007760.txt

## Citations
- 0001829126-26-007760 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000182912626007760